Search News
| 31.99 Delayed Data As of 4:00pm ET |  +0.01 / +0.03%Today’s Change | 16.33 Today|||52-Week Range 35.99 | +66.44% Year-to-Date |
| Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)? Sep 12 / Zacks.com - Paid Partner Content | Should You Invest in the ARK Innovation ETF (ARKK)? Sep 10 / Zacks.com - Paid Partner Content |
| Previous close | 31.98 |
| Today’s open | 31.51 |
| Day’s range | 31.51 - 32.70 |
| Volume | 539,478 |
| Average volume (3 months) | 768,980 |
| Market cap | $1.4B |
| Earnings growth (last year) | -32.39% |
| Earnings growth (this year) | -7.02% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +58.49% |
| P/E ratio | NM |
| Price/Sales | 26.50 |
| Price/Book | 4.51 |
| Today’s change | Today’s % change | |
|---|---|---|
| DCPHDeciphera Pharmaceut... | +0.28 | +0.78% |
| IMGNImmunoGen Inc | -0.22 | -2.43% |
| QUREUniqure NV | -1.34 | -3.36% |
| BOLDAudentes Therapeutic... | -0.67 | -1.67% |
| Next reporting date | October 30, 2018 |
| EPS forecast (this quarter) | -$0.48 |
| Annual revenue (last year) | $26.1M |
| Annual profit (last year) | -$67.5M |
| Net profit margin | -258.62% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director John M. Leonard |
Executive Vice President & General Counsel Jose E. Rivera |
Corporate headquarters Cambridge, Massachusetts |
